Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03580655
Recruitment Status : Active, not recruiting
First Posted : July 9, 2018
Last Update Posted : December 21, 2020
Sponsor:
Information provided by (Responsible Party):
Blueprint Medicines Corporation

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2022